Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Nov 05, 2022 1:39pm
637 Views
Post# 35075813

Monday

MondayThings to think about before Monday morning. 

A look on clincialtrials shows 245 cancer studies presently recruiting or active:

https://clinicaltrials.gov/ct2/results?cond=Cancer&term=&type=&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=DE&state=&city=hamburg&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=

A look at Dirk Arnolds linkedin shows hiim describing Goblet as one of AIO's "major trials"
https://it.linkedin.com/posts/dirk-arnold-7482a178_goblet-a-phase-iii-study-of-pelareorep-activity-6956625803358916608-v5VF?trk=public_profile_like_view

And it is interesting to see former Medical Officer Rita Laeufle reminding everyone that she designed the Goblet trial:
https://it.linkedin.com/posts/dirk-arnold-7482a178_oncolytics-activity-6990895915318321152-dxlj
<< Previous
Bullboard Posts
Next >>